CCCC
C4 Therapeutics, Inc.
Biotechnology · Healthcare · United States
3.37
close · 2026-10-30
value
20
cheaper than peers20
quality
34
stronger fundamentals34
ranked against
Biotechnology (commercial)
value
quality
162 peerswide variation
Value inputs
| measure | company | vs peers |
| price to book | 1.67× | 78 |
| price to sales | 11.83× | 48 |
| cash flow yield, 1 year ago | -15.8% | 39 |
| cash flow yield, 2 years ago | -26.2% | 30 |
| cash flow yield, latest year | -24.0% | 30 |
| earnings yield, latest year | -37.7% | 28 |
| earnings yield, 1 year ago | -45.1% | 26 |
| cash flow yield, 3 years ago | -26.9% | 26 |
| earnings yield, 3 years ago | -77.7% | 24 |
| earnings yield, 2 years ago | -79.2% | 20 |
10 of 12 measures available
Quality inputs
| measure | company | vs peers |
| return on equity | -48.1% | 51 |
| debt to equity | 23.0% | 44 |
| revenue growth | 2.8% | 38 |
| operating margin | -397.9% | 37 |
4 of 4 measures available
Facts
| market cap | $415M |
| free cash flow | -$43.7M |
| employees | 104 |
| first trade | 2020-10-02 |
| next earnings | 2026-08-11 |
| fundamentals updated | 2026-08-14 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -1.27 | -1.52 | -2.67 | -2.62 |
| free cash flow | -$99.3M | -$65.3M | -$108.5M | -$111.4M |
| net income | -$105.0M | -$105.3M | -$132.5M | -$128.2M |
| revenue | $35.9M | $35.6M | $20.8M | $31.1M |
| unusual items | -$10.7M | -$2.4M | -$621,000 | $0 |